idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Science Video Project
idw-Abo

idw-News App:

AppStore

Google Play Store



Instanz:
Teilen: 
19.01.2017 10:45

Scientist from Kiel University coordinates Million Euros Project in Inflammation Research

Dr. Boris Pawlowski Presse, Kommunikation und Marketing
Christian-Albrechts-Universität zu Kiel

    Comprehensive EU Funding Programme Supports Personalised Medicine Approaches
    The international consortium of the new European research project SYSCID (“A systems medicine approach to chronic inflammatory disease“) aims to develop a personalised medicine approach for inflammatory bowel disease, rheumatoid arthritis and systemic lupus erythematosus. The project coordinated by Kiel University in Germany (CAU) receives a total funding of 14.4 million Euros for a period of five years. Out of this budget Kiel University receives almost three million Euros.

    Academic and industry partners from nine different countries join forces to achieve the ambitious goals of the project which has started at the beginning of 2017.

    With a lifetime prevalence of over ten percent in the EU, chronic inflammatory disease (CID) poses a major health care burden to modern society. “Our vision is to develop a prediction framework for disease outcome and choice of treatment strategies. With many new targeted therapies coming to the market, we need the right therapy at the right time,” said Professor Philip Rosenstiel from the Institute of Clinical Molecular Biology at Kiel University and scientific coordinator of the SYSCID consortium. “Our approach combines several biomarker layers from the epigenome to the microbiome, but also aims to investigate more sophisticated tools, such as single cell analysis.”

    The new epigenetic markers could be more significant than inflammation markers in the blood which have been used so far. As these ‘traditional’ markers also increase in patients with a common cold or elevated temperature, they cannot always be allocated clearly.

    SYSCID will use dense clinical sampling and molecular phenotyping to analyse longitudinal patient cohorts and obtain a deeper understanding of the immunological network changes associated with response and non-response to current treatment regimes. Unlike current therapeutic interventions which mainly alleviate the symptoms, SYSCID aims to develop a therapeutic strategy that will eventually offer a first causal therapy. The consortium targets new therapy approaches by ‘reprogramming’ disease through epigenome editing. “Assuming that the development and course of a disease are related to long-term epigenetic alterations, it makes sense to target the very root of the disease,” Rosenstiel said.

    SYSCID will build on previous and ongoing research activities by partners and international initiatives such as the International Human Epigenome Consortium (IHEC) with the aim of exploiting already collected and established patient data and enabling their utilisation for the development of new clinical applications. Moreover, the project will create training opportunities and career perspectives for young European scientists with its findings serving as a blueprint for future development of precision medicine in other fields.

    Contact
    Kiel University, Institute of Clinical Molecular Biology
    Prof. Dr Philip Rosenstiel
    Tel.: +49(0)431/500 15111
    p.rosenstiel@mucosa.de

    Dr. Tebke Böschen
    Tel.: +49(431) 880-4682
    E-Mail: tboeschen@uv.uni-kiel.de

    Further Information

    Project acronym: SYSCID
    Start date: 01 January 2017
    Duration: 63 months
    Budget: € 14.4 Mio
    Coordination: Kiel University, Germany

    SYSCID Partners at a glance

    Belgium
    University of Leuven

    Croatia
    Genos

    Denmark
    University of Southern Denmark

    Germany
    Kiel University
    Comma Soft AG
    European Research and Project Office GmbH
    Saarland University
    University of Bonn

    Greece
    Biomedical Research Foundation of the Academy of Athens

    Italy
    Humanitas University

    Luxemburg
    University of Luxemburg

    Switzerland
    University of Geneva

    UK
    King´s College London
    University of Cambridge


    Weitere Informationen:

    http://www.uni-kiel.de/pressemeldungen/index.php?pmid=2017-010-horizon-2020-foer...


    Bilder

    Merkmale dieser Pressemitteilung:
    Journalisten
    Medizin
    überregional
    Forschungsprojekte
    Englisch


     

    Hilfe

    Die Suche / Erweiterte Suche im idw-Archiv
    Verknüpfungen

    Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.

    Klammern

    Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).

    Wortgruppen

    Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.

    Auswahlkriterien

    Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).

    Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).